alexa A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity.
Medicine

Medicine

Anatomy & Physiology: Current Research

Author(s): Micieli JA, Surkont M, Smith AF

Abstract Share this page

Abstract PURPOSE: To examine the quality of evidence and the variability in the off-label use of bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) in the treatment of retinopathy of prematurity (ROP) and to discuss the implications for the design of future randomized controlled trials. DESIGN: Systematic literature review. METHODS: A systematic review of the literature indexed by Ovid MEDLINE, EMBASE, and the Cochrane database was performed with a broad and inclusive search strategy. All case reports and retrospective and prospective trials in peer-reviewed journals reporting the use of bevacizumab in ROP were included. RESULTS: Nine articles, including 6 case reports, 2 retrospective studies, and 1 prospective case series representing 77 eyes of 48 infants, were selected for the review. The doses used ranged from 0.4 to 1.25 mg, with 0.75 mg being the most common, used in 3 of the 9 studies. A total of 8 of the 11 eyes in the case received bevacizumab as a first-line therapy and two articles noted worsening of an already present retinal detachment. One retrospective study and the prospective case series used bevacizumab alone, whereas the other retrospective study used bevacizumab before and with retinal surgery. CONCLUSIONS: Considerable variability exists in how bevacizumab is used for the treatment of ROP in the literature to date. Further randomized control trials are warranted and should aim to assess statistically the optimal timing, frequency, and dose of the drug. Careful attention should be given to the potential for systemic complications and long-term effects of intravitreal bevacizumab in infants. This article was published in Am J Ophthalmol and referenced in Anatomy & Physiology: Current Research

Relevant Expert PPTs

Relevant Speaker PPTs

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords